Dihexa — Vendor Pricing & Purity Guide
Research Overview
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic peptide derivative developed at Washington State University by Dr. Joseph Harding's laboratory. It is an analog of angiotensin IV that was designed to activate the hepatocyte growth factor (HGF)/c-Met receptor system. Dihexa has generated significant interest in the nootropic community due to its extraordinary potency — it is reported to be 10 million times more potent than BDNF at promoting new synaptic connections.
Dihexa works by stabilizing the HGF/c-Met signaling pathway, which promotes synaptogenesis (formation of new synapses), neurogenesis, and dendritic spine growth. The HGF/c-Met system is critical for brain development and repair, and its decline with age correlates with cognitive deterioration. By amplifying this pathway, Dihexa has demonstrated profound cognitive enhancement in animal models of dementia and cognitive decline.
Despite its remarkable preclinical data, Dihexa remains a very early-stage research compound with no human clinical trial data. Its extreme potency (active at picomolar concentrations) raises questions about long-term safety, and the HGF/c-Met pathway is also involved in cancer metastasis — a concern that requires further investigation.
Key Research Findings
- •10 million-fold more potent than BDNF at forming new synaptic connections in vitro
- •Restored cognitive function in aged rats to levels comparable to young animals in spatial memory tests
- •Promoted synaptogenesis and dendritic spine growth through HGF/c-Met receptor stabilization
- •Active at picomolar concentrations — among the most potent cognitive-enhancing compounds discovered
- •Reversed scopolamine-induced cognitive deficits in animal models
- •Orally bioavailable in animal models — unusual for peptide-derived compounds
Research Dosage Protocols
Dihexa is supplied as lyophilized powder. Due to its extreme potency (active at picomolar concentrations), very small doses are used in research. Published animal studies used doses in the range of 0.1-2 mg/kg.
Dihexa has demonstrated oral bioavailability in animal models. It is also studied via subcutaneous injection and intranasal administration.
Researchers should note the lack of human safety data and the theoretical concern regarding HGF/c-Met pathway activation in cancer biology. Long-term safety studies have not been conducted.
For research reference only. Not medical advice. Not for human consumption.
Price Comparison (5 products from 4 vendors)
| Vendor | Price | Stock |
|---|---|---|
| Swiss Chems | $97.99 $0.20/mg 500mg vial | In Stock |
| Swiss Chems | $69.99 $14.00/mg 5mg capsule | In Stock |
| NextChems | $69.99 $14.00/mg 5mg capsule | In Stock |
| Skye Peptides | $119.00 $14.88/mg 8mg capsule | In Stock |
| Peptide Sciences | $195.00 $39.00/mg 5mg capsule | In Stock |
Frequently Asked Questions
What is Dihexa?
Dihexa is a synthetic peptide derivative that promotes new synapse formation through the HGF/c-Met pathway. It is reported to be 10 million times more potent than BDNF and restored cognitive function in aged rats to youthful levels.
Is Dihexa safe?
No human clinical trials have been conducted. The HGF/c-Met pathway it activates is also involved in cancer metastasis, which is a theoretical concern requiring further research. Its extreme potency at picomolar concentrations also warrants caution.
Where can I buy Dihexa for research?
Dihexa is available from select research peptide vendors. Compare pricing in the table above.